Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medicare Part D Redesign Could Expand Rebate-Driven Formulary Exclusions In Program

Executive Summary

Increased application of utilization management controls expected as plans face higher costs under the redesign. However, the formulary advantages available to drugs in the protected classes may lead developers to sharpen their focus on those categories.

You may also be interested in...

Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign

Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.

‘Sleeper Issue:’ How Part B Drugs May Be Impacted By Medicare Part D Redesign

If changes to stand-alone Part D plans mandated by the IRA drive a switch to MA plans, the changing enrollment could drive more uptake of physician-administered drugs – but also more utilization management.

Part D In 2024: Premium Increases, Shrinking Choices Signal Early Impact Of IRA Redesign

More impactful benefit changes coming in 2025; will destabilization among standalone plans follow?

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts